R&D A new dawn of the genomic age: five areas set to be transfor... 2022 was a banner year for genomics.
News Bayer bolsters R&D platform with $2bn Vividion takeover Bayer headlined its second-quarter results this morning by unveiling a deal to buy Vividion Therapeutics, saying it will boost its ability to develop medicines against targets once consider
Partner Content Partner Content 6th Annual Single Cell Analysis USA Congress 2 days, 350+ end users, 80+ case studies
News UK project addresses capacity issue in CGT manufacturing A UK consortium has been set up to tackle a major issue in the development of cell and gene therapies (CGT) – a lack of manufacturing capacity.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
